Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT

NCT07779031 is registered in ClinicalTrials.gov with Liping Dou as lead sponsor.

NCT NCT07779031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07779031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT
Lead sponsor
Liping Dou
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 1, 2025
Completion date
May 1, 2028
Enrollment
58 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukaemia (aml), mds (myelodysplastic syndrome)